Here’s the updated Diagnostic Techniques content based on current guidelines (ACS, NCCN, ACR 2024):
Diagnostic Techniques
When a routine screening reveals a suspicious area, further testing is necessary to determine whether the change is benign or malignant. The diagnostic process may involve imaging, tissue sampling, or advanced genomic testing depending on your individual situation. No single test tells the complete picture — your health care team will recommend the combination most appropriate for you.
If you have questions about what it’s like to experience any of these techniques, call the Y-ME 24/7 Breast Cancer Support Center at 800-221-2141 and speak with someone who has been through it. Peer counselors who are breast cancer survivors are available anytime, day or night.
Needle Biopsy and Fine Needle Aspiration (FNA)
A needle biopsy is one of the most common ways to determine whether a suspicious area contains cancer cells. There are several types:
Fine Needle Aspiration (FNA) uses a thin needle to withdraw fluid or a small number of cells from a lump or suspicious area. It is quick, minimally invasive, and can often be performed in a clinic without special preparation. FNA is frequently used to evaluate cysts or palpable lumps, though it may not always provide enough tissue for a definitive diagnosis.
Core Needle Biopsy (CNB) uses a slightly larger, hollow needle to remove small cylinders (cores) of tissue. It is the preferred biopsy method in most cases because it provides more tissue for histologic analysis, allowing pathologists to determine not just whether cancer is present but also its grade, hormone receptor status (ER/PR), and HER2 expression. CNB is typically performed with imaging guidance — ultrasound, stereotactic mammography, or MRI — to ensure accuracy.
Vacuum-Assisted Biopsy (VAB) is a variation of core needle biopsy that uses suction to collect multiple tissue samples through a single needle insertion. It is commonly used for microcalcifications identified on mammography and can remove larger tissue volumes than standard CNB.
Results from a needle biopsy are typically available within a few days and are evaluated by a pathologist whose report guides your treatment plan.
Needle Localization (Wire or Seed Localization)
Needle localization is a pre-surgical procedure used when a suspicious area — such as microcalcifications or a non-palpable lesion — cannot be felt by hand. It helps the surgeon precisely locate and remove the area during a lumpectomy or excisional biopsy.
In traditional wire localization, a thin wire is inserted into the breast under mammographic or ultrasound guidance on the morning of surgery. The surgeon uses the wire as a guide to remove the target tissue.
Newer approaches include radioactive seed localization (RSL) and magnetic seed localization (Magseed), in which a tiny marker is placed days before surgery, offering more scheduling flexibility and eliminating the discomfort of a same-day wire placement. These newer methods are increasingly preferred at comprehensive breast centers.
After the tissue is removed, a specimen radiograph is taken immediately in the operating room to confirm that the target area has been successfully excised.
Ultrasound (Sonography)
Breast ultrasound uses high-frequency sound waves to create real-time images of breast tissue. Unlike mammography, it does not use radiation, making it safe for repeated use and appropriate during pregnancy.
Ultrasound is particularly effective at distinguishing between fluid-filled cysts (which are almost always benign) and solid masses that may require further evaluation. It is commonly used:
- As a follow-up to an abnormal mammogram or MRI
- To guide needle biopsies with real-time imaging precision
- In women with dense breast tissue, where mammography alone may be less sensitive
- For evaluating palpable lumps in younger women
Automated Whole-Breast Ultrasound (ABUS) is an emerging technology approved by the FDA as a supplemental screening tool for women with dense breasts, and is increasingly offered alongside mammography at larger imaging centers.
Ultrasound alone is not recommended as a primary screening tool but is a valuable component of a comprehensive diagnostic workup.
MRI (Magnetic Resonance Imaging)
Breast MRI uses powerful magnets and radio waves — no radiation — combined with a contrast agent (gadolinium, injected intravenously) to produce highly detailed images of breast tissue. It is the most sensitive imaging tool currently available for breast cancer detection.
MRI is not used as a routine screening tool for most women, but current NCCN and ACS guidelines (2024) recommend annual breast MRI alongside mammography for women who are at high risk, including those with:
- A BRCA1 or BRCA2 gene mutation
- A lifetime breast cancer risk of 20% or greater based on risk assessment models
- A history of chest radiation between ages 10 and 30
- Certain genetic syndromes such as Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba
MRI is also used diagnostically to assess the extent of known cancer before surgery, evaluate the opposite breast after a new diagnosis, monitor response to neoadjuvant chemotherapy, and investigate cases where cancer is found in a lymph node but no primary tumor is visible on mammogram or ultrasound (occult primary breast cancer).
A limitation of breast MRI is a higher rate of false positives compared to mammography, which can lead to additional biopsies of ultimately benign findings.
Mammography
Mammography remains the gold standard for breast cancer screening and plays a central role in diagnosis. It uses low-dose X-rays to image breast tissue and can detect abnormalities — including microcalcifications, masses, and architectural distortions — often years before a lump can be felt.
Screening mammography involves routine imaging in women without symptoms. Current major guideline recommendations vary slightly:
- ACS (2024): Annual mammograms recommended starting at age 45, with the option to begin at 40. Women 55 and older may switch to every two years or continue annually.
- USPSTF (2024, updated): Recommends biennial mammograms starting at age 40.
- ACR and SBI: Recommend annual mammograms starting at age 40 for average-risk women.
Women with dense breasts, a family history, or other risk factors should discuss earlier or more frequent screening with their doctor.
Diagnostic mammography is used when a woman has symptoms (a lump, nipple discharge, skin changes) or when a screening mammogram shows an abnormality. It includes additional targeted views and is interpreted immediately by a radiologist.
3D Mammography (Digital Breast Tomosynthesis or DBT) is now widely available and is the current standard of care at most imaging centers. DBT takes multiple X-ray images at different angles to create a three-dimensional picture of the breast, significantly improving cancer detection rates and reducing false positives — particularly in women with dense breast tissue.
Oncotype DX
Oncotype DX is a genomic test that analyzes the activity of 21 genes within a breast cancer tumor to predict the likelihood of cancer recurrence and to assess whether a patient is likely to benefit from chemotherapy in addition to hormone therapy.
It is currently indicated for women with:
- Early-stage (Stage I or II), hormone receptor-positive (ER+), HER2-negative invasive breast cancer
- Node-negative or 1–3 positive lymph nodes
The test produces a Recurrence Score (RS) from 0 to 100:
- Low score (0–17): Chemotherapy is unlikely to provide benefit; hormone therapy alone is typically recommended
- Intermediate score (18–30): The decision is individualized, with consideration of patient age and menopausal status
- High score (31+): Chemotherapy is likely to provide significant benefit
The landmark TAILORx trial validated the use of Oncotype DX in guiding chemotherapy decisions, and it is now a standard part of treatment planning in eligible patients per NCCN, ASCO, and ESMO guidelines.
MammaPrint
MammaPrint is a genomic assay that measures the activity of 70 genes to classify early-stage breast cancer as either low genomic risk or high genomic risk for distant recurrence within 10 years.
It is used for women with:
- Stage I or II, hormone receptor-positive or negative, HER2-negative breast cancer
- Tumors up to 5 cm in size
- Node-negative or 1–3 positive lymph nodes
The MINDACT trial, a large European study, demonstrated that a significant proportion of women classified as high clinical risk but low genomic risk by MammaPrint could safely forgo chemotherapy without compromising survival outcomes.
MammaPrint is FDA-cleared and recognized in NCCN guidelines as a valid tool for informing chemotherapy decisions. It is sometimes used alongside Agilprint (a companion molecular subtyping test) to provide additional context about tumor biology.
The choice between MammaPrint and Oncotype DX is typically guided by tumor characteristics, physician preference, and insurance coverage, as both are validated tools serving similar clinical purposes.
A Note on Emerging Diagnostics
Diagnostic technology continues to evolve rapidly. Tools now entering clinical practice or under active evaluation include:
- Liquid biopsy, which detects circulating tumor DNA (ctDNA) in blood to monitor treatment response or early recurrence
- Contrast-Enhanced Mammography (CEM), which offers sensitivity approaching MRI at lower cost
- **AI-assisted mammography reading, which is increasingly used to improve radiologist accuracy and reduce missed cancers
Ask your health care team whether any of these newer options may be relevant to your diagnosis.
For peer support from someone who has personally experienced any of these diagnostic procedures, contact the Y-ME National Breast Cancer Organization support line at 800-221-2141, available 24 hours a day, 7 days a week.
